Peerview Clinical Pharmacology Cme/cne/cpe Audio Podcast

Go online to PeerView.com/EHE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Elevated low-density lipoprotein cholesterol (LDL-C) levels are causally related to the risk of atherosclerotic cardiovascular disease (ASCVD)—justifying the guidance from multiple professional societies that emphasize the importance of lowering LDL-C to reduce cardiovascular risk. Despite the availability of nearly ten different classes of medications indicated to lower cholesterol levels, dyslipidemia is not appropriately managed for many patients, resulting in target LDL-C goals not being achieved. In this activity, based on a recent live symposium, experts discuss targeted therapies to optimize lipid management, including primary and secondary prevention of CV events, with PCSK9-targeting therapies (in particular, PCSK9 antibodies and novel small interfering RNAs). Upon completion of this activity, participants should be better able to: Apply current hyperlipidemia treatment